Understanding Ocular Graft-Versus-Host Disease After Bone Marrow Transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a territory-wide cohort of patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) to investigate ocular graft-versus-host disease (oGVHD). The study will focus on the prevalence and impact of oGVHD, which affects a significant percentage of HSCT patients and can lead to severe complications such as visual loss. By collecting microbiome and tear samples from patients and their family members, the researchers hope to identify risk factors and improve management strategies for oGVHD. The study is conducted in collaboration with the Department of Haematology at Queen Mary Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged 18 or above
* Underwent allogeneic HSCT in QMH in the two-year recruitment period

Exclusion Criteria:

* Underwent autologous HSCT
* Patient unable to attend follow-up visits

Family Control Subjects The research team will invite an accompanying family member to be the family control. Microbiome and tear samples will be collected for comparison. The sample collection schedule is the same as the corresponding post-HSCT case.

Where it's running

• Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Allie Lee — The University of Hong Kong
• Study coordinator: Allie Lee
• Email: aleeni@hku.hk
• Phone: +852 39621405

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Madecassoside tablets plus standard therapy for sclered scl-cGVHD after allo-HSCT

  This study tests whether adding madecassoside tablets to standard therapy can help people with scleral chronic graft-versus-host disease after stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07606703

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Fatigue and thinking problems after allogeneic stem cell transplant (synapse damage or brain GVHD)

  This project uses PET scans and spinal fluid samples to try to find why people who had an allogeneic stem cell transplant have persistent fatigue and thinking problems.

  Recruiting Karolinska University Hospital · Stockholm · NCT07365696

• Fecal microbiota transplantation for steroid-refractory acute GI-GvHD

  This trial tests whether fecal microbiota transplantation can help adults with steroid-refractory acute gastrointestinal graft-versus-host disease after stem cell transplant.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan · NCT07364617

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.